Skip to main content

Fesik Lab

A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A.

AUTHORS

Souza-Fagundes EMElaine M , Frank AO Andreas O , Feldkamp MD Michael D , Dorset DC Daniel C , Chazin WJ Walter J , Rossanese OW Olivia W , Olejniczak ET Edward T , Fesik SW Stephen W . Analytical biochemistry. 2012 2 15; 421(2). 742-9

ABSTRACT

Replication protein A (RPA) interacts with multiple checkpoint proteins and promotes signaling through the ATR kinase, a key regulator of checkpoint pathways in the mammalian response to DNA damage. In cancer cells, increased DNA repair activity contributes to resistance to chemotherapy. Therefore, small molecules that block binding of checkpoint proteins to RPA may inhibit the DNA damage response and, thus, sensitize cancer cells to DNA-damaging agents. Here we report on the development of a homogeneous, high-throughput fluorescence polarization assay for identifying compounds that block the critical protein-protein interaction site in the basic cleft of the 70N domain of RPA (RPA70N). A fluorescein isothiocyanate (FITC)-labeled peptide derived from the ATR cofactor, ATRIP, was used as a probe in the binding assay. The ability of the assay to accurately detect relevant ligands was confirmed using peptides derived from ATRIP, RAD9, MRE11, and p53. The assay was validated for use in high-throughput screening using the Spectrum collection of 2000 compounds. The FPA assay was performed with a Z’ factor of ≥ 0.76 in a 384-well format and identified several compounds capable of inhibiting the RPA70N binding interface.